Khalid Al-ghamdy1 and Ishtiaq Qadri2
1Department of Biological Sciences, Faculty of Science, King Abdul-Aziz University, Jeddah, KSA
2Head Virology, Department of Biological Sciences, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia
*Corresponding Author: Ishtiaq Qadri, Head Virology, Department of Biological Sciences, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia.
Received: December 12, 2019; Published: January 06, 2020
Dengue virus is a mosquito borne flavivirus and cusses 50 million infection each year. The spread of the virus through the female mosquito Aedes egypti or Aedes albopictus is very fast and containment strategies are constantly explored to stop the infection into human. Due to topographical dissemination of these mosquito vectors, over 2 billion individuals are at risk of contracting the infection and dengue hemorrhage fever (DHF). The disease in now epidemic to over 100 countries and 4 different serotypes have been reported from the insects and human. So far the containment and vaccine strategies are not effective to control the mosquito and spread of virus. Several countries have attempted to develop vaccines but are largely in clinical phases trials and result indict that such vaccines are not strong immunogenic against all Dengue serotypes. A live attenuated tetravalent chimeric vaccine Dengvaxia, is commercially available in limited high risk areas of Thailand and Brazil. The plasmid for vaccine was constructed by replacing the yellow fever attenuated 17D strain with that of the pre-membrane (PreM and Envelope (E) region of four dengue serotypes Unpublished reports indicate from phase 3 clinical trials with 31,000 children of 2 - 14 years, that efficacy with Dengvaxia was 50 to 60%. An inactivated tetravalent vaccine (TDEN PIV) is jointly developed by GSK and the Walter Reed Army Institute which is based on a synergistic (boost) concept. In this scheme the immunogenicity, of primary vaccine is enhanced with another serotype. Pharmaceutical giant Merck is in the process of developing a subunit vaccine based on fruit fly D. melanogaster Schneider cells. All these efforts are in the initial stages of development. Therefore, multiple approaches are obligatory for mosquito eradication, such as biological control, insecticide and new antivirals strategies to inhibit virus translation and replication.
Keywords: Sixth Nerve Palsy; Chikungunya Virus Infection
Citation: Khalid Al-ghamdy and Ishtiaq Qadri. “Biological Control of Aedes Egypti and Dengue Virus with Bacteria Wolbachia". Acta Scientific Microbiology 3.2 (2020): 22.
Copyright: © 2020 Khalid Al-ghamdy and Ishtiaq Qadri. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.